Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress - 2Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- 3Artemis II's moonbound toilet is working again to astronauts' relief after overnight fix
- 4'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- 5Bruno Mars tour 2026: How to get tickets for 'The Romantic Tour,' presale times, prices and more
- Find the Native Culinary Customs: Local Flavors
- Pick Your Favored pizza beating
- Congolese rape survivors search in vain for medicine after USAID cuts
- Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- The race to mine the moon is on – and it urgently needs some clear international rules
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- Israeli archaeologists launch project to trace origins of ancient pottery
